Hyperglycaemia is the hallmark of diabetes mellitus. It is a complicated chronic metabolic disease. These problems, which have long-term detrimental effects on key organs, including the eyes, kidneys, heart, and brain, and increase patient mortality, can be categorized as either microvascular or macrovascular complications based on the various pathophysiological causes. The incidence and prevalence of diabetes mellitus have dramatically increased in recent years, making it a serious worldwide health concern. Furthermore, as more people embrace a Western diet and lifestyle, the incidence is predicted to keep rising. About one-third to one-half of diabetics suffer from organ and tissue damage as a result of the disease’s strong correlation with both microvascular and macrovascular complications such as retinopathy, nephropathy, and neuropathy (microvascular) and ischemic heart disease, peripheral vascular disease, and cerebrovascular disease (macrovascular). Vascular problems contribute significantly to diabetes mellitus (DM), globally accounting for 26.8% of cases. About 20% to 30% of diabetic patients experience macrovascular problems, which greatly increase the morbidity and death rate of type 2 diabetes. Patients with diabetes have significant increases in morbidity and a severe reduction in their quality of life due to microvascular problems. In this review, we will discuss both macrovascular and microvascular complications of diabetes mellitus, its mechanism, novel diagnostic tools, and treatment strategies in detail.
References
[1]
World Health Organization (2024) Diabetes. https://www.who.int/health-topics/diabetes#tab=tab_1
[2]
UK Prospective Diabetes Study (UKPDS) (1991) UK Prospective Diabetes Study. Diabetologia, 34, 877-890. https://doi.org/10.1007/bf00400195
[3]
Rahman, S., Rahman, T., Ismail, A.A. and Rashid, A.R.A. (2006) Diabetes-Associated Macrovasculopathy: Pathophysiology and Pathogenesis. Diabetes, Obesity and Metabolism, 9, 767-780. https://doi.org/10.1111/j.1463-1326.2006.00655.x
[4]
Cade, W.T. (2008) Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. Physical Therapy, 88, 1322-1335. https://doi.org/10.2522/ptj.20080008
[5]
Lu, Y., Wang, W., Liu, J., Xie, M., Liu, Q. and Li, S. (2023) Vascular Complications of Diabetes: A Narrative Review. Medicine, 102, e35285. https://doi.org/10.1097/md.0000000000035285
[6]
Khalil, H. (2017) Diabetes Microvascular Complications—A Clinical Update. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 11, S133-S139. https://doi.org/10.1016/j.dsx.2016.12.022
[7]
Hu, M., Ma, Q., Liu, B., Wang, Q., Zhang, T., Huang, T., et al. (2022) Long Non-Coding RNAs in the Pathogenesis of Diabetic Kidney Disease. Frontiers in Cell and Developmental Biology, 10, Article 845371. https://doi.org/10.3389/fcell.2022.845371
[8]
Chen, Y., He, Y. and Zhou, H. (2020) The Potential Role of lncRNAs in Diabetes and Diabetic Microvascular Complications. Endocrine Journal, 67, 659-668. https://doi.org/10.1507/endocrj.ej19-0574
[9]
Grant, P.J. (2007) Diabetes Mellitus as a Prothrombotic Condition. Journal of Internal Medicine, 262, 157-172. https://doi.org/10.1111/j.1365-2796.2007.01824.x
[10]
Huang, D., Refaat, M., Mohammedi, K., Jayyousi, A., Al Suwaidi, J. and Abi Khalil, C. (2017) Macrovascular Complications in Patients with Diabetes and Prediabetes. BioMed Research International, 2017, 1-9. https://doi.org/10.1155/2017/7839101
[11]
World Health Organization (2024) Noncommunicable Diseases: Risk Factors and Conditions. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-risk-factors
[12]
Institute for Health Metrics and Evaluation (2024) Global Burden of Disease Collaborative Network. Global Burden of Disease Study.
[13]
Paul, S., Ali, A. and Katare, R. (2020) Molecular Complexities Underlying the Vascular Complications of Diabetes Mellitus—A Comprehensive Review. Journal of Diabetes and its Complications, 34, Article 107613. https://doi.org/10.1016/j.jdiacomp.2020.107613
[14]
Arnold, S.V., Khunti, K., Tang, F., Chen, H., Cid-Ruzafa, J., Cooper, A., et al. (2022) Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global Discover Study. American Heart Journal, 243, 232-239. https://doi.org/10.1016/j.ahj.2021.10.181
[15]
Gregg, E.W., Li, Y., Wang, J., Rios Burrows, N., Ali, M.K., Rolka, D., et al. (2014) Changes in Diabetes-Related Complications in the United States, 1990-2010. New England Journal of Medicine, 370, 1514-1523. https://doi.org/10.1056/nejmoa1310799
[16]
Fox, C.S. (2004) Trends in Cardiovascular Complications of Diabetes. Journal of the American Medical Association, 292, 2495-2499. https://doi.org/10.1001/jama.292.20.2495
[17]
Bethel, M.A. (2007) Longitudinal Incidence and Prevalence of Adverse Outcomes of Diabetes Mellitus in Elderly Patients. Archives of Internal Medicine, 167, 921-927. https://doi.org/10.1001/archinte.167.9.921
[18]
McAllister, D.A., Read, S.H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., et al. (2018) Incidence of Hospitalization for Heart Failure and Case-Fatality among 3.25 Million People with and without Diabetes Mellitus. Circulation, 138, 2774-2786. https://doi.org/10.1161/circulationaha.118.034986
[19]
Shah, A.D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C.P., et al. (2015) Type 2 Diabetes and Incidence of Cardiovascular Diseases: A Cohort Study in 1·9 Million People. The Lancet Diabetes & Endocrinology, 3, 105-113. https://doi.org/10.1016/s2213-8587(14)70219-0
[20]
Birkeland, K.I., Bodegard, J., Eriksson, J.W., Norhammar, A., Haller, H., Linssen, G.C.M., et al. (2020) Heart Failure and Chronic Kidney Disease Manifestation and Mortality Risk Associations in Type 2 Diabetes: A Large Multinational Cohort Study. Diabetes, Obesity and Metabolism, 22, 1607-1618. https://doi.org/10.1111/dom.14074
[21]
An, J., Nichols, G.A., Qian, L., Munis, M.A., Harrison, T.N., Li, Z., et al. (2021) Prevalence and Incidence of Microvascular and Macrovascular Complications over 15 Years among Patients with Incident Type 2 Diabetes. BMJ Open Diabetes Research & Care, 9, e001847. https://doi.org/10.1136/bmjdrc-2020-001847
[22]
World Health Organization (2024) Diabetes Facts. https://www.who.int/news-room/fact-sheets/detail/diabetes
[23]
Harding, S. (2003) Extracts from “Concise Clinical Evidence”: Diabetic Retinopathy Commentary: Treatment of Diabetic Retinopathy. British Medical Journal, 326, 1023-1025. https://doi.org/10.1136/bmj.326.7397.1023
[24]
Sheetz, M.J. (2002) Molecular Understanding of Hyperglycemia’s Adverse Effects for Diabetic Complications. Journal of the American Medical Association, 288, 2579-2588. https://doi.org/10.1001/jama.288.20.2579
[25]
Orchard, T.J., Dorman, J.S., Maser, R.E., Becker, D.J., Drash, A.L., Ellis, D., et al. (1990) Prevalence of Complications in IDDM by Sex and Duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes, 39, 1116-1124. https://doi.org/10.2337/diabetes.39.9.1116
[26]
Romero-Aroca, P., Baget-Bernaldiz, M., Pareja-Rios, A., Lopez-Galvez, M., Navarro-Gil, R. and Verges, R. (2016) Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. Journal of Diabetes Research, 2016, 1-17. https://doi.org/10.1155/2016/2156273
[27]
Kempen, J.H., O’Colmain, B.J., Leske, M.C., et al. (2004) The Prevalence of Diabetic Retinopathy among Adults in the United States. Archives of ophthalmology, 122, 552-563.
[28]
Klein, R. (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of Ophthalmology, 102, 527-532. https://doi.org/10.1001/archopht.1984.01040030405011
[29]
Tyrberg, M., Melander, A., Lövestam-Adrian, M. and Lindblad, U. (2008) Retinopathy in Subjects with Impaired Fasting Glucose: The Nansy-Eye Baseline Report. Diabetes, Obesity and Metabolism, 10, 646-651. https://doi.org/10.1111/j.1463-1326.2007.00759.x
[30]
Brazionis, L., Rowley, K., Itsiopoulos, C., Harper, C.A. and O’Dea, K. (2008) Homocysteine and Diabetic Retinopathy. Diabetes Care, 31, 50-56. https://doi.org/10.2337/dc07-0632
[31]
Wang, W. and Lo, A.C.Y. (2018) Diabetic Retinopathy: Pathophysiology and Treatments. International Journal of Molecular Sciences, 19, Article 1816. https://doi.org/10.3390/ijms19061816
[32]
Fong, D.S., Aiello, L.P., Ferris, F.L. and Klein, R. (2004) Diabetic Retinopathy. Diabetes Care, 27, 2540-2553. https://doi.org/10.2337/diacare.27.10.2540
[33]
Wong, T.Y., Klein, R., Couper, D.J., Cooper, L.S., Shahar, E., Hubbard, L.D., et al. (2001) Retinal Microvascular Abnormalities and Incident Stroke: The Atherosclerosis Risk in Communities Study. The Lancet, 358, 1134-1140. https://doi.org/10.1016/s0140-6736(01)06253-5
[34]
Fuller, J., Stevens, L. and Wang, S. (2001) Risk Factors for Cardiovascular Mortality and Morbidity: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 44, S54-S64. https://doi.org/10.1007/pl00002940
[35]
Yatsuya, H., Folsom, A.R., Wong, T.Y., Klein, R., Klein, B.E.K. and Sharrett, A.R. (2010) Retinal Microvascular Abnormalities and Risk of Lacunar Stroke. Stroke, 41, 1349-1355. https://doi.org/10.1161/strokeaha.110.580837
[36]
Wilkinson-Berka, J.L. (2004) Diabetes and Retinal Vascular Disorders: Role of the Renin–Angiotensin System. Expert Reviews in Molecular Medicine, 6, 1-18. https://doi.org/10.1017/s1462399404008129
[37]
Yamagishi, S. and Imaizumi, T. (2005) Pericyte Biology and Diseases. International Journal of Tissue Reactions, 27, 125-135.
[38]
Rajala, U., Pajunpää, H., Koskela, P. and Keinänen-Kiukaanniemi, S. (2000) High Cardiovascular Disease Mortality in Subjects with Visual Impairment Caused by Diabetic Retinopathy. Diabetes Care, 23, 957-961. https://doi.org/10.2337/diacare.23.7.957
[39]
Yamagishi, S., Kobayashi, K. and Yamamoto, H. (1993) Vascular Pericytes Not Only Regulate Growth, but Also Preserve Prostacyclin-Producing Ability and Protect against Lipid Peroxide-Induced Injury of Cocultured Endothelial Cells. Biochemical and Biophysical Research Communications, 190, 418-425. https://doi.org/10.1006/bbrc.1993.1064
[40]
Carlson, E.C., Audette, J.L., Veitenheimer, N.J., Risan, J.A., Laturnus, D.I. and Epstein, P.N. (2003) Ultrastructural Morphometry of Capillary Basement Membrane Thickness in Normal and Transgenic Diabetic Mice. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 271, 332-341. https://doi.org/10.1002/ar.a.10038
[41]
Hammes, H.-P. (2005) Pericytes and the Pathogenesis of Diabetic Retinopathy. Hormone and Metabolic Research, 37, 39-43. https://doi.org/10.1055/s-2005-861361
[42]
Brownlee, M. (2005) The Pathobiology of Diabetic Complications. Diabetes, 54, 1615-1625. https://doi.org/10.2337/diabetes.54.6.1615
[43]
Bek, T. (2017) Diameter Changes of Retinal Vessels in Diabetic Retinopathy. Current Diabetes Reports, 17, Article No. 82. https://doi.org/10.1007/s11892-017-0909-9
[44]
Naruse, K., Nakamura, J., Hamada, Y., Nakayama, M., Chaya, S., Komori, T., et al. (2000) Aldose Reductase Inhibition Prevents Glucose-Induced Apoptosis in Cultured Bovine Retinal Microvascular Pericytes. Experimental Eye Research, 71, 309-315. https://doi.org/10.1006/exer.2000.0882
[45]
Romeo, G., Liu, W., Asnaghi, V., Kern, T.S. and Lorenzi, M. (2002) Activation of Nuclear Factor-κB Induced by Diabetes and High Glucose Regulates a Proapoptotic Program in Retinal Pericytes. Diabetes, 51, 2241-2248. https://doi.org/10.2337/diabetes.51.7.2241
[46]
Ejaz, S., Chekarova, I., Ejaz, A., Sohail, A. and Lim, C.W. (2007) Importance of Pericytes and Mechanisms of Pericyte Loss during Diabetic Retinopathy. Diabetes, Obesity and Metabolism, 10, 53-63. https://doi.org/10.1111/j.1463-1326.2007.00795.x
[47]
Beltramo, E. and Porta, M. (2013) Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences. Current Medicinal Chemistry, 20, 3218-3225. https://doi.org/10.2174/09298673113209990022
[48]
Huang, H., He, J., Johnson, D., Wei, Y., Liu, Y., Wang, S., et al. (2014) Deletion of Placental Growth Factor Prevents Diabetic Retinopathy and Is Associated with Akt Activation and HIF1α-VEGF Pathway Inhibition. Diabetes, 64, 200-212. https://doi.org/10.2337/db14-0016
[49]
Lupo, G., Motta, C., Giurdanella, G., Anfuso, C.D., Alberghina, M., Drago, F., et al. (2013) Role of Phospholipases A2 in Diabetic Retinopathy: In Vitro and in Vivo Studies. Biochemical Pharmacology, 86, 1603-1613. https://doi.org/10.1016/j.bcp.2013.09.008
[50]
Antonetti, D.A., Barber, A.J., Hollinger, L.A., Wolpert, E.B. and Gardner, T.W. (1999) Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1. Journal of Biological Chemistry, 274, 23463-23467. https://doi.org/10.1074/jbc.274.33.23463
[51]
Rousseau, S., Houle, F., Landry, J. and Huot, J. (1997) P38 MAP Kinase Activation by Vascular Endothelial Growth Factor Mediates Actin Reorganization and Cell Migration in Human Endothelial Cells. Oncogene, 15, 2169-2177. https://doi.org/10.1038/sj.onc.1201380
[52]
Li, J., Wang, J.J., Yu, Q., Chen, K., Mahadev, K. and Zhang, S.X. (2010) Inhibition of Reactive Oxygen Species by Lovastatin Downregulates Vascular Endothelial Growth Factor Expression and Ameliorates Blood-Retinal Barrier Breakdown in db/db Mice. Diabetes, 59, 1528-1538. https://doi.org/10.2337/db09-1057
[53]
Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., et al. (1994) Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. New England Journal of Medicine, 331, 1480-1487. https://doi.org/10.1056/nejm199412013312203
[54]
Pober, J.S. and Sessa, W.C. (2007) Evolving Functions of Endothelial Cells in Inflammation. Nature Reviews Immunology, 7, 803-815. https://doi.org/10.1038/nri2171
[55]
Sang, D.N. and D’Amore, P.A. (2008) Is Blockade of Vascular Endothelial Growth Factor Beneficial for All Types of Diabetic Retinopathy? Diabetologia, 51, 1570-1573. https://doi.org/10.1007/s00125-008-1078-9
[56]
Centers for Disease Control and Prevention (2007) Diabetes: Minorities Face Greater Burden, CDC National Diabetes Fact Sheet.
Brownlee, M. (2001) Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature, 414, 813-820. https://doi.org/10.1038/414813a
[59]
Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H., et al. (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345, 861-869. https://doi.org/10.1056/nejmoa011161
[60]
Drummond, K. and Mauer, M. (2002) The Early Natural History of Nephropathy in Type 1 Diabetes. Diabetes, 51, 1580-1587. https://doi.org/10.2337/diabetes.51.5.1580
[61]
Gross, J.L., de Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L. and Zelmanovitz, T. (2005) Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care, 28, 164-176. https://doi.org/10.2337/diacare.28.1.164
[62]
Soedamah-Muthu, S.S., Chaturvedi, N., Witte, D.R., Stevens, L.K., Porta, M. and Fuller, J.H. (2008) Relationship between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe. Diabetes Care, 31, 1360-1366. https://doi.org/10.2337/dc08-0107
[63]
Hovind, P., Tarnow, L., Rossing, P., Graae, M., Torp, I., Binder, C., et al. (2004) Predictors for the Development of Microalbuminuria and Macroalbuminuria in Patients with Type 1 Diabetes: Inception Cohort Study. British Medical Journal, 328, 1105. https://doi.org/10.1136/bmj.38070.450891.fe
[64]
Adler, A.I., Stevens, R.J., Manley, S.E., Bilous, R.W., Cull, C.A., Holman, R.R., et al. (2003) Development and Progression of Nephropathy in Type 2 Diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International, 63, 225-232. https://doi.org/10.1046/j.1523-1755.2003.00712.x
[65]
Trevisan, R., Dodesini, A.R. and Lepore, G. (2006) Lipids and Renal Disease. Journal of the American Society of Nephrology, 17, S145-S147. https://doi.org/10.1681/asn.2005121320
[66]
Arora, G.S., Chawla, R. and Ahuja, C.P. (2008) To Evaluate the Clinical Profile and Determine the Prevalence of Complications in Newly Detected Type-2 Diabetes Patients. Research Society for the Study of Diabetes in India, Bangalore, September 2008, 77-82.
[67]
Fowler, M.J. (2008) Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes, 26, 77-82. https://doi.org/10.2337/diaclin.26.2.77
[68]
Hägg, S., Thorn, L.M., Putaala, J., Liebkind, R., Harjutsalo, V., Forsblom, C.M., et al. (2013) Incidence of Stroke According to Presence of Diabetic Nephropathy and Severe Diabetic Retinopathy in Patients with Type 1 Diabetes. Diabetes Care, 36, 4140-4146. https://doi.org/10.2337/dc13-0669
[69]
Lloyd, C.E., Klein, R., Maser, R.E., Kuller, L.H., Becker, D.J. and Orchard, T.J. (1995) The Progression of Retinopathy over 2 Years: The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. Journal of Diabetes and its Complications, 9, 140-148. https://doi.org/10.1016/1056-8727(94)00039-q
[70]
Tong, P.C.Y., Kong, A.P.S., So, W., Ng, M.H.L., Yang, X., Ng, M.C.Y., et al. (2006) Hematocrit, Independent of Chronic Kidney Disease, Predicts Adverse Cardiovascular Outcomes in Chinese Patients with Type 2 Diabetes. Diabetes Care, 29, 2439-2444. https://doi.org/10.2337/dc06-0887
[71]
Ang, L., Jaiswal, M., Martin, C. and Pop-Busui, R. (2014) Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Current Diabetes Reports, 14, Article No. 528. https://doi.org/10.1007/s11892-014-0528-7
[72]
Pop-Busui, R., Lu, J., Brooks, M.M., Albert, S., Althouse, A.D., Escobedo, J., et al. (2013) Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care, 36, 3208-3215. https://doi.org/10.2337/dc13-0012
[73]
Franklin, G.M., Kahn, L.B., Baxter, J., Marshall, J.A. And Hamman, R.F. (1990) Sensory Neuropathy In Non-Insulin-Dependent Diabetes Mellitus. American Journal of Epidemiology, 131, 633-643. https://doi.org/10.1093/oxfordjournals.aje.a115547
[74]
Thrainsdottir, S., Malik, R.A., Dahlin, L.B., Wiksell, P., Eriksson, K.F., Rosén, I., et al. (2003) Endoneurial Capillary Abnormalities Presage Deterioration of Glucose Tolerance and Accompany Peripheral Neuropathy in Man. Diabetes, 52, 2615-2622. https://doi.org/10.2337/diabetes.52.10.2615
[75]
Malik, R.A., Newrick, P.G., Sharma, A.K., Jennings, A., Ah-See, A.K., Mayhew, T.M., et al. (1989) Microangiopathy in Human Diabetic Neuropathy: Relationship between Capillary Abnormalities and the Severity of Neuropathy. Diabetologia, 32, 92-102. https://doi.org/10.1007/bf00505180
[76]
Pop-Busui, R., Boulton, A.J.M., Feldman, E.L., Bril, V., Freeman, R., Malik, R.A., etal. (2016) Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 40, 136-154. https://doi.org/10.2337/dc16-2042
[77]
Gordois, A., Scuffham, P., Shearer, A., Oglesby, A. and Tobian, J.A. (2003) The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S. Diabetes Care, 26, 1790-1795. https://doi.org/10.2337/diacare.26.6.1790
[78]
Italian General Practitioner Study Group (IGPSG) (1995) Chronic Symmetric Symptomatic Polyneuropathy in the Elderly: A Field Screening Investigation in Two Italian Regions. I. Prevalence and General Characteristics of the Sample. Neurology, 45, 1832-1836.
[79]
Bharucha, N.E., Bharucha, A.E. and Bharucha, E.P. (1991) Prevalence of Peripheral Neuropathy in the Parsi Community of Bombay. Neurology, 41, 1315-1315. https://doi.org/10.1212/wnl.41.8.1315
[80]
Callaghan, B.C., Kerber, K.A., Lisabeth, L.L., Morgenstern, L.B., Longoria, R., Rodgers, A., et al. (2014) Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurology, 71, 1143-1149. https://doi.org/10.1001/jamaneurol.2014.1279
[81]
Visser, N.A., Notermans, N.C., Linssen, R.S.N., van den Berg, L.H. and Vrancken, A.F.J.E. (2015) Incidence of Polyneuropathy in Utrecht, the Netherlands. Neurology, 84, 259-264. https://doi.org/10.1212/wnl.0000000000001160
[82]
Dyck, P.J., Kratz, K.M., Karnes, J.L., Litchy, W.J., Klein, R., Pach, J.M., et al. (1993) The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population-Based Cohort. Neurology, 43, 817-817. https://doi.org/10.1212/wnl.43.4.817
[83]
Tesfaye, S., Chaturvedi, N., Eaton, S.E.M., Ward, J.D., Manes, C., Ionescu-Tirgoviste, C., et al. (2005) Vascular Risk Factors and Diabetic Neuropathy. New England Journal of Medicine, 352, 341-350. https://doi.org/10.1056/nejmoa032782
[84]
Partanen, J., Niskanen, L., Lehtinen, J., Mervaala, E., Siitonen, O. and Uusitupa, M. (1995) Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 333, 89-94. https://doi.org/10.1056/nejm199507133330203
[85]
Andersen, S.T., Witte, D.R., Dalsgaard, E., Andersen, H., Nawroth, P., Fleming, T., etal. (2018) Risk Factors for Incident Diabetic Polyneuropathy in a Cohort with Screen-Detected Type 2 Diabetes Followed for 13 Years: Addition-Denmark. Diabetes Care, 41, 1068-1075. https://doi.org/10.2337/dc17-2062
Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T.B., Schnell, O., et al. (2019) Diabetes as a Cardiovascular Risk Factor: An Overview of Global Trends of Macro and Micro Vascular Complications. European Journal of Preventive Cardiology, 26, 25-32. https://doi.org/10.1177/2047487319878371
[88]
Tang, H., Fang, Z., Wang, T., Cui, W., Zhai, S. and Song, Y. (2016) Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality among Patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology, 118, 1774-1780. https://doi.org/10.1016/j.amjcard.2016.08.061
[89]
Lee, C., Wu, Y., Kuo, J., Chen, J., Chin, M. and Hung, Y. (2019) Prevalence of Diabetic Macrovascular Complications and Related Factors from 2005 to 2014 in Taiwan Region: A Nationwide Survey. Journal of the Formosan Medical Association, 118, S96-S102. https://doi.org/10.1016/j.jfma.2019.08.035
[90]
Beckman, J.A., Paneni, F., Cosentino, F. and Creager, M.A. (2013) Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II. European Heart Journal, 34, 2444-2452. https://doi.org/10.1093/eurheartj/eht142
[91]
Buyken, A.E., von Eckardstein, A., Schulte, H., Cullen, P. and Assmann, G. (2007) Type 2 Diabetes Mellitus and Risk of Coronary Heart Disease: Results of the 10-Year Follow-Up of the PROCAM Study. European Journal of Cardiovascular Prevention & Rehabilitation, 14, 230-236. https://doi.org/10.1097/hjr.0b013e3280142037
[92]
Malakar, A.K., Choudhury, D., Halder, B., Paul, P., Uddin, A. and Chakraborty, S. (2019) A Review on Coronary Artery Disease, Its Risk Factors, and Therapeutics. Journal of Cellular Physiology, 234, 16812-16823. https://doi.org/10.1002/jcp.28350
[93]
Einarson, T.R., Acs, A., Ludwig, C. and Panton, U.H. (2018) Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence from across the World in 2007–2017. Cardiovascular Diabetology, 17, Article No. 83. https://doi.org/10.1186/s12933-018-0728-6
[94]
The Emerging Risk Factors Collaboration (2010) Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. The Lancet, 375, 2215-2222. https://doi.org/10.1016/s0140-6736(10)60484-9
[95]
Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K. and Laakso, M. (1998) Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. New England Journal ofMedicine, 339, 229-234. https://doi.org/10.1056/nejm199807233390404
[96]
Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J. and Idris, I. (2009) Is Diabetes a Coronary Risk Equivalent? Systematic Review and Meta-Analysis. Diabetic Medicine, 26, 142-148. https://doi.org/10.1111/j.1464-5491.2008.02640.x
[97]
Tonyan, Z.N., Nasykhova, Y.A., Danilova, M.M. and Glotov, A.S. (2021) Genetics of Macrovascular Complications in Type 2 Diabetes. World Journal of Diabetes, 12, 1200-1219. https://doi.org/10.4239/wjd.v12.i8.1200
[98]
Romon, I., Fosse, S., Eschwège, E., Simon, D., Weill, A., Varroud-Vial, M., et al. (2008) Prevalence of Macrovascular Complications and Cardiovascular Risk Factors in People Treated for Diabetes and Living in France: The ENTRED Study 2001. Diabetes & Metabolism, 34, 140-147. https://doi.org/10.1016/j.diabet.2007.11.002
[99]
Boyle, P.J. (2007) Diabetes Mellitus and Macrovascular Disease: Mechanisms and Mediators. The American Journal of Medicine, 120, S12-S17. https://doi.org/10.1016/j.amjmed.2007.07.003
[100]
Beckman, J.A., Creager, M.A. and Libby, P. (2002) Diabetes and Atherosclerosis. Journal of the American Medical Association, 287, 2570-2581. https://doi.org/10.1001/jama.287.19.2570
[101]
Laing, S.P., Swerdlow, A.J., Slater, S.D., Burden, A.C., Morris, A., Waugh, N.R., et al. (2003) Mortality from Heart Disease in a Cohort of 23,000 Patients with Insulin-Treated Diabetes. Diabetologia, 46, 760-765. https://doi.org/10.1007/s00125-003-1116-6
[102]
Paterson, A.D., Rutledge, B.N., Cleary, P.A., Lachin, J.M. and Crow, R.S. (2007) The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes. Diabetes Care, 30, 2107-2112. https://doi.org/10.2337/dc06-1441
[103]
Hogan, P., Dall, T. and Nikolov, P. (2003) Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care, 26, 917-932. https://doi.org/10.2337/diacare.26.3.917
[104]
Kannel, W.B. (1979) Diabetes and Cardiovascular Disease. Journal of the American Medical Association, 241, 2035-2038. https://doi.org/10.1001/jama.1979.03290450033020
[105]
Tonomura, S., Ihara, M. and Friedland, R.P. (2020) Microbiota in Cerebrovascular Disease: A Key Player and Future Therapeutic Target. Journal of Cerebral Blood Flow & Metabolism, 40, 1368-1380. https://doi.org/10.1177/0271678x20918031
[106]
Virani, S.S., Alonso, A., Aparicio, H.J., et al. (2021) Heart Disease and Stroke Statistics—2021 Update: A Report from the American Heart Association. Circulation, 143, e254-e743.
[107]
Guo, L., Yu, M., Zhong, J., Wu, H., Pan, J., Gong, W., et al. (2016) Stroke Risk among Patients with Type 2 Diabetes Mellitus in Zhejiang: A Population-Based Prospective Study in China. International Journal of Endocrinology, 2016, 1-8. https://doi.org/10.1155/2016/6380620
[108]
Proietti, M., Mairesse, G.H., Goethals, P., Scavee, C., Vijgen, J., Blankoff, I., et al. (2016) Cerebrovascular Disease, Associated Risk Factors and Antithrombotic Therapy in a Population Screening Cohort: Insights from the Belgian Heart Rhythm Week Programme. European Journal of Preventive Cardiology, 24, 328-334. https://doi.org/10.1177/2047487316682349
[109]
Oe, M., Fujihara, K., Harada-Yamada, M., Osawa, T., Kitazawa, M., Matsubayashi, Y., et al. (2021) Impact of Prior Cerebrovascular Disease and Glucose Status on Incident Cerebrovascular Disease in Japanese. Cardiovascular Diabetology, 20, Article No. 174. https://doi.org/10.1186/s12933-021-01367-7
[110]
Rocco, A., Heerlein, K., Diedler, J., Sykora, M., Barrows, R., Hacke, W., et al. (2010) Microalbuminuria in Cerebrovascular Disease: A Modifiable Risk Factor? International Journal of Stroke, 5, 30-34. https://doi.org/10.1111/j.1747-4949.2009.00398.x
[111]
Griessenauer, C.J., Farrell, S., Sarkar, A., Zand, R., Abedi, V., Holland, N., et al. (2018) Genetic Susceptibility to Cerebrovascular Disease: A Systematic Review. Journal of Cerebral Blood Flow & Metabolism, 38, 1853-1871. https://doi.org/10.1177/0271678x18797958
[112]
Della-Morte, D., Pacifici, F. and Rundek, T. (2016) Genetic Susceptibility to Cerebrovascular Disease. Current Opinion in Lipidology, 27, 187-195. https://doi.org/10.1097/mol.0000000000000275
[113]
Gretarsdottir, S., Thorleifsson, G., Manolescu, A., Styrkarsdottir, U., Helgadottir, A., Gschwendtner, A., et al. (2008) Risk Variants for Atrial Fibrillation on Chromosome 4q25 Associate with Ischemic Stroke. Annals of Neurology, 64, 402-409. https://doi.org/10.1002/ana.21480
[114]
Gudbjartsson, D.F., Holm, H., Gretarsdottir, S., Thorleifsson, G., Walters, G.B., Thorgeirsson, G., et al. (2009) A Sequence Variant in ZFHX3 on 16q22 Associates with Atrial Fibrillation and Ischemic Stroke. Nature Genetics, 41, 876-878. https://doi.org/10.1038/ng.417
[115]
Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. New England Journal of Medicine, 340, 115-126. https://doi.org/10.1056/nejm199901143400207
[116]
Orellana-Urzúa, S., Rojas, I., Líbano, L. and Rodrigo, R. (2020) Pathophysiology of Ischemic Stroke: Role of Oxidative Stress. Current Pharmaceutical Design, 26, 4246-4260. https://doi.org/10.2174/1381612826666200708133912
[117]
Abramov, A.Y., Scorziello, A. and Duchen, M.R. (2007) Three Distinct Mechanisms Generate Oxygen Free Radicals in Neurons and Contribute to Cell Death during Anoxia and Reoxygenation. The Journal of Neuroscience, 27, 1129-1138. https://doi.org/10.1523/jneurosci.4468-06.2007
[118]
American Diabetes Association (2003) Peripheral Arterial Disease in People with Diabetes. Diabetes Care, 26, 3333-3341. https://doi.org/10.2337/diacare.26.12.3333
[119]
Hirsch, A.T. (2001) Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. Journal of the American Medical Association, 286, 1317-1324. https://doi.org/10.1001/jama.286.11.1317
[120]
Reaven, P.D. and Sacks, J. (2005) Coronary Artery and Abdominal Aortic Calcification Are Associated with Cardiovascular Disease in Type 2 Diabetes. Diabetologia, 48, 379-385. https://doi.org/10.1007/s00125-004-1640-z
[121]
Walsh, J.A., Prineas, R., Daviglus, M.L., Ning, H., Liu, K., Lewis, C.E., et al. (2010) Prevalence of Electrocardiographic Abnormalities in a Middle-Aged, Biracial Population: Coronary Artery Risk Development in Young Adults Study. Journal of Electrocardiology, 43, 385.e1-385.e9. https://doi.org/10.1016/j.jelectrocard.2010.02.001
[122]
Thiruvoipati, T. (2015) Peripheral Artery Disease in Patients with Diabetes: Epidemiology, Mechanisms, and Outcomes. World Journal of Diabetes, 6, 961-969. https://doi.org/10.4239/wjd.v6.i7.961
[123]
Lange, S., Diehm, C., Darius, H., Haberl, R., Allenberg, J.R., Pittrow, D., et al. (2003) High Prevalence of Peripheral Arterial Disease but Low Antiplatelet Treatment Rates in Elderly Primary Care Patients with Diabetes. Diabetes Care, 26, 3357-3358. https://doi.org/10.2337/diacare.26.12.3357
[124]
Diehm, C., Schuster, A., Allenberg, J.R., Darius, H., Haberl, R., Lange, S., et al. (2004) High Prevalence of Peripheral Arterial Disease and Co-Morbidity in 6880 Primary Care Patients: Cross-Sectional Study. Atherosclerosis, 172, 95-105. https://doi.org/10.1016/s0021-9150(03)00204-1
[125]
Hiatt, W.R., Fowkes, F.G.R., Heizer, G., Berger, J.S., Baumgartner, I., Held, P., et al. (2017) Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine, 376, 32-40. https://doi.org/10.1056/nejmoa1611688
[126]
Weragoda, J., Seneviratne, R., Weerasinghe, M.C. and Wijeyaratne, S. (2016) Risk Factors of Peripheral Arterial Disease: A Case Control Study in Sri Lanka. BMC Research Notes, 9, Article No. 508. https://doi.org/10.1186/s13104-016-2314-x
[127]
Paneni, F., Beckman, J.A., Creager, M.A. and Cosentino, F. (2013) Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. European Heart Journal, 34, 2436-2443. https://doi.org/10.1093/eurheartj/eht149
[128]
Cheng, P. and Kao, C. (2021) Postprandial Plasma Glucose Excursion Is Associated with an Atherogenic Lipid Profile in Individuals with Type 2 Diabetes Mellitus: A Cross-Sectional Study. PLOS ONE, 16, e0258771. https://doi.org/10.1371/journal.pone.0258771
[129]
Troili, F., Cipollini, V., Moci, M., Morena, E., Palotai, M., Rinaldi, V., et al. (2020) Corrigendum: Perivascular Unit: This Must Be the Place. the Anatomical Crossroad between the Immune, Vascular and Nervous System. Frontiers in Neuroanatomy, 14, Article 51. https://doi.org/10.3389/fnana.2020.00051
[130]
Da Moura Semedo, C., Webb, M., Waller, H., Khunti, K. and Davies, M. (2017) Skin Autofluorescence, a Non-Invasive Marker of Advanced Glycation End Products: Clinical Relevance and Limitations. Postgraduate Medical Journal, 93, 289-294. https://doi.org/10.1136/postgradmedj-2016-134579
[131]
Li, M., Popovic, Z., Chu, C., Reichetzeder, C., Pommer, W., Krämer, B.K., et al. (2023) Impact of Angiopoietin-2 on Kidney Diseases. Kidney Diseases, 9, 143-156. https://doi.org/10.1159/000529774
[132]
Chen, W., Chen, K., Xu, Z., Hu, Y., Liu, Y., Liu, W., et al. (2021) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict Mortality in Patients with Diabetic Foot Ulcers Undergoing Amputations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 821-829. https://doi.org/10.2147/dmso.s284583
[133]
Zeng, J., Chen, M., Feng, Q., Wan, H., Wang, J., Yang, F., et al. (2022) The Platelet-To-Lymphocyte Ratio Predicts Diabetic Retinopathy in Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 3617-3626. https://doi.org/10.2147/dmso.s378284
[134]
Serban, D., Papanas, N., Dascalu, A.M., Kempler, P., Raz, I., Rizvi, A.A., et al. (2021) Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets. The International Journal of Lower Extremity Wounds, 23, 205-216. https://doi.org/10.1177/15347346211057742
[135]
Abdelhalim, A.S., Abdelkader, M.F.S.O., Mahmoud, M.S.E. and Mohamed Mohamed, A.A. (2022) Macular Vessel Density before and after Panretinal Photocoagulation in Patients with Proliferative Diabetic Retinopathy. International Journal of Retina and Vitreous, 8, Article No. 21. https://doi.org/10.1186/s40942-022-00369-1
[136]
Faghihi, H., Riazi-Esfahani, H., Khodabande, A., Khalili Pour, E., Mirshahi, A., Ghassemi, F., et al. (2020) Effect of Panretinal Photocoagulation on Macular Vasculature Using Optical Coherence Tomography Angiography. European Journal of Ophthalmology, 31, 1877-1884. https://doi.org/10.1177/1120672120952642
[137]
Li, Y., Ren, Q., Sun, C., Li, L., Lian, H., Sun, R., et al. (2022) Efficacy and Mechanism of Anti-Vascular Endothelial Growth Factor Drugs for Diabetic Macular Edema Patients. World Journal of Diabetes, 13, 532-542. https://doi.org/10.4239/wjd.v13.i7.532
[138]
Boyer, D.S., Hopkins, J.J., Sorof, J. and Ehrlich, J.S. (2013) Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Therapeutic Advances in Endocrinology and Metabolism, 4, 151-169. https://doi.org/10.1177/2042018813512360
